Close

Infinity Pharmaceutical (INFI) 'Overvalued'; Wedbush Starts at Underperform

March 3, 2014 4:50 PM EST Send to a Friend
Wedbush initiated coverage on Infinity Pharmaceutical (NASDAQ: INFI) with an Underperform rating and price target of $10.00. Analyst David M ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login